

Trovogene, Inc.  
Form 8-K  
September 18, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 17, 2014**

**Trovogene, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**001-35558**  
(Commission File  
Number)

**27-2004382**  
IRS Employer  
Identification No.)

**11055 Flintkote Avenue, Suite B**

**San Diego, CA 92121**

(Address of principal executive offices)

Registrant's telephone number, including area code: **(858) 952-7570**

(Former name or former address, if changed since last report)

## Edgar Filing: Trovogene, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On September 17, 2014, Trovogene, Inc. (the Company) held its Annual Meeting of Stockholders (the Annual Meeting). A total of 11,434,328 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on July 23, 2014, as supplemented, are as follows:

*Proposal 1.* All of the seven (7) nominees for director were elected to serve until the 2015 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the seven (7) directors was as follows:

Directors	For	Withhold	Broker Non-Vote
Dr. Paul Billings	3,952,882	24,864	7,456,582
Gary S. Jacob	3,935,442	42,304	7,456,582
Thomas H. Adams	9,949,624	28,122	7,456,582
John P. Brancaccio	3,932,374	45,372	7,456,582
Antonius Schuh	3,948,599	29,147	7,456,582
Dr. Stanley Tennant	3,952,632	25,114	7,456,582
Dr. Rodney S. Markin	3,951,282	26,464	7,456,582

*Proposal 2.* The appointment of BDO USA, LLP as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2014 was ratified and approved by the stockholders by the votes set forth in the table below:

For	Against	Abstain	Broker Non Vote
10,437,216	996,587	525	0

*Proposal 3.* The adoption of the Company's 2014 Equity Incentive Plan and the reservation of 2,500,000 shares of common stock for issuance thereunder was ratified and approved by the stockholders by the votes set forth in the table below:

For	Against	Abstain	Broker Non Vote
3,330,577	611,680	35,489	7,456,582

Edgar Filing: Trovogene, Inc. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 18, 2014

TROVAGENE, INC.

By: */s/ Antonius Schuh*  
Antonius Schuh  
Chief Executive Officer